Modulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of tribbles pseudokinase 1 expression

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Nagiec, Marek M ^a   Skepner, Adam P ^a   Negri, Joseph ^a   Eichhorn, Michelle ^a   Kuperwasser, Nicolas ^b   Comer, Eamon ^a   Muncipinto, Giovanni ^a   Subramanian, Aravind ^a   Clish, Clary ^a   Musunuru, Kiran ^b   Duvall, Jeremy R ^a   Foley, Michael ^a   Perez, Jose R ^a   Palmer, Michelle A J ^a  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b Harvard University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; BENZOFURAN DERIVATIVE; CASPASE 9; COMPLEMENTARY DNA; CRISPR ASSOCIATED PROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PROTEIN PCSK9; PROTEIN TRIB1; REGULATOR PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOSTATIN M; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TRIB1 PROTEIN, HUMAN;

ARTICLE; CHOLESTEROL METABOLISM; CHROMOSOME; DOWN REGULATION; GENE DISRUPTION; GENE LOCUS; HEPATOMA CELL; HEPG2 CELL LINE; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; LIPOGENESIS; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UPREGULATION; CLUSTER ANALYSIS; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; HIGH THROUGHPUT SCREENING; LIPID METABOLISM; LIVER CELL; METABOLISM; MOLECULAR LIBRARY;

CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPID METABOLISM; LIPOPROTEINS; LIPOPROTEINS, LDL; MITOGEN-ACTIVATED PROTEIN KINASES; ONCOSTATIN M; PROTEIN SERINE-THREONINE KINASES; SMALL MOLECULE LIBRARIES;

EID: 84926211891     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120295     Document Type: Article

References (57)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation. 2011; 123(4):e18-e209. Epub 2010/12/17. doi: CIR.0b013e3182009701 [pii] doi: 10.1161/CIR.0b013e3182009701 PMID: 21160056.
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr., Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004; 44(3):720-32. Epub 2004/09/11. doi: 10.1016/j.jacc.2004.07.001S0735109704013312 [pii]. PMID: 15358046.
3. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011; 32(11):1345-61. doi: 10.1093/eurheartj/ehr112 PMID: 21531743; PubMed Central PMCID: PMC3105250.
4. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013; 45(11):1345-52. doi: 10.1038/ng.2795 PMID: 24097064.
5. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012; 380(9836):29-36. doi: 10.1016/S0140-6736(12)60771-5 PMID: 22633824.
6. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012; 367(20):1891-900. doi: 10.1056/NEJMoa1201832 PMID: 23113833.
7. Desai NR, Kohli P, Giugliano RP, O'Donoghue M, Somaratne R, Zhou J, et al. AMG 145, A Monoclonal Antibody Against PCSK9, Significantly Reduces Lipoprotein (a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LAPLACE-TIMI 57 Trial. Circulation. 2013; 128(9):962-9. doi: 10.1161/CIRCULATIONAHA.113.001969 PMID: 23884353.
8. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012; 126(20):2408-17. doi: 10.1161/CIRCULATIONAHA.112.144055 PMID: 23129602.
9. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013; 381(9860):40-6. doi: 10.1016/S0140-6736(12)61731-0 PMID: 23122768.
10. Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012; 126(19):2283-92. doi: 10.1161/CIRCULATIONAHA.112.104125 PMID: 23060426.
11. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011; 123 (20):2292-333. doi: 10.1161/CIR.0b013e3182160726 PMID: 21502576.
12. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010; 466(7307):707-13. Epub 2010/08/06. doi: nature09270 [pii] doi: 10.1038/nature09270 PMID: 20686565; PubMed Central PMCID: PMC3039276.
13. Ishizuka Y, Nakayama K, Ogawa A, Makishima S, Boonvisut S, Hirao A, et al. TRIB1 downregulates hepatic lipogenesis and glycogenesis via multiple molecular interactions. Journal of molecular endocrinology. 2014; 52(2):145-58. doi: 10.1530/JME-13-0243 PMID: 24389359.
14. Burkhardt R, Toh SA, Lagor WR, Birkeland A, Levin M, Li X, et al. Trib1 is a lipid- and myocardial infarc-tion- associated gene that regulates hepatic lipogenesis and VLDL production in mice. J Clin Invest. 2010; 120(12):4410-4. Epub 2010/11/19. doi: 44213 [pii] doi: 10.1172/JCI44213 PMID: 21084752; PubMed Central PMCID: PMC2993600.
15. Kiss-Toth E. Tribbles: 'puzzling' regulators of cell signalling. Biochem Soc Trans. 2011; 39(2):684-7. Epub 2011/03/25. doi: BST0390684 [pii] doi: 10.1042/BST0390684 PMID: 21428962.
16. Sung HY, Guan H, Czibula A, King AR, Eder K, Heath E, et al. Human tribbles-1 controls proliferation and chemotaxis of smooth muscle cells via MAPK signaling pathways. J Biol Chem. 2007; 282 (25):18379-87. Epub 2007/04/25. doi: M610792200 [pii] doi: 10.1074/jbc.M610792200 PMID: 17452330; PubMed Central PMCID: PMC2366084.
17. Satoh T, Kidoya H, Naito H, Yamamoto M, Takemura N, Nakagawa K, et al. Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages. Nature. 2013; 495(7442):524-8. doi: 10.1038/nature11930 PMID: 23515163.
18. Liang KL, Rishi L, Keeshan K. Tribbles in acute leukemia. Blood. 2013; 121(21):4265-70. doi: 10.1182/blood-2012-12-471300 PMID: 23550039.
19. Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet. 2011; 43 (11):1131-8. Epub 2011/10/18. doi: ng.970 [pii] doi: 10.1038/ng.970 PMID: 22001757; PubMed Central PMCID: PMC3482372.
20. Ollila HM, Utge S, Kronholm E, Aho V, Van Leeuwen W, Silander K, et al. TRIB1 constitutes a molecular link between regulation of sleep and lipid metabolism in humans. Transl Psychiatry. 2012; 2:e97. Epub 2012/07/27. doi: tp201220 [pii] doi: 10.1038/tp.2012.20 PMID: 22832862; PubMed Central PMCID: PMC3316154.
21. Schreiber SL. Organic chemistry: Molecular diversity by design. Nature. 2009; 457(7226):153-4. doi: 10.1038/457153a PMID: 19129834.
22. Marcaurelle LA, Comer E, Dandapani S, Duvall JR, Gerard B, Kesavan S, et al. An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors. Journal of the American Chemical Society. 2010; 132(47):16962-76. doi: 10.1021/ja105119r PMID: 21067169; PubMed Central PMCID: PMC3004530.
23. Lowe JT, Lee MDt, Akella LB, Davoine E, Donckele EJ, Durak L, et al. Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries. The Journal of organic chemistry. 2012; 77(17):7187-211. doi: 10.1021/jo300974j PMID: 22853001; PubMed Central PMCID: PMC3454511.
24. Gerard B, Lee MDt, Dandapani S, Duvall JR, Fitzgerald ME, Kesavan S, et al. Synthesis of stereochemically and skeletally diverse fused ring systems from functionalized C-glycosides. The Journal of organic chemistry. 2013; 78(11):5160-71. doi: 10.1021/jo4000916 PMID: 23692141; PubMed Central PMCID: PMC3752688.
25. Schaefer GI, Perez JR, Duvall JR, Stanton BZ, Shamji AF, Schreiber SL. Discovery of small-molecule modulators of the Sonic Hedgehog pathway. Journal of the American Chemical Society. 2013; 135 (26):9675-80. doi: 10.1021/ja400034k PMID: 23725514; PubMed Central PMCID: PMC3703668.
26. Chou DH, Duvall JR, Gerard B, Liu H, Pandya BA, Suh BC, et al. Synthesis of a novel suppressor of beta-cell apoptosis via diversity-oriented synthesis. ACS Med Chem Lett. 2011; 2(9):698-702. doi: 10.1021/ml200120m PMID: 21927648; PubMed Central PMCID: PMC3171963.
27. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nature protocols. 2008; 3(6):1101-8. PMID: 18546601.
28. Duan Q, Flynn C, Niepel M, Hafner M, Muhlich JL, Fernandez NF, et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res. 2014; 42(W1):W449-W60. doi: 10.1093/nar/gku476 PMID: 24906883.
29. Peck D, Crawford ED, Ross KN, Stegmaier K, Golub TR, Lamb J. A method for high-throughput gene expression signature analysis. Genome biology. 2006; 7(7):R61. doi: 10.1186/gb-2006-7-7-r61 PMID: 16859521; PubMed Central PMCID: PMC1779561.
30. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicological sciences: an official journal of the Society of Toxicology. 2007; 97(2):539-47. doi: 10.1093/toxsci/kfm052 PMID: 17361016.
31. Soubeyrand S, Naing T, Martinuk A, McPherson R. ERK1/2 regulates hepatocyte Trib1 in response to mitochondrial dysfunction. Biochim Biophys Acta. 2013; 1833(12):3405-14. doi: 10.1016/j.bbamcr.2013.10.001 PMID: 24161842.
32. Cao A, Wu M, Li H, Liu J. Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells. J Lipid Res. 2011; 52(3):518-30. Epub 2011/01/05. doi: jlr.M010603 [pii] doi: 10.1194/jlr.M010603 PMID: 21196532; PubMed Central PMCID: PMC3035688.
33. Sharova LV, Sharov AA, Nedorezov T, Piao Y, Shaik N, Ko MS. Database for mRNA half-life of 19 977 genes obtained by DNA microarray analysis of pluripotent and differentiating mouse embryonic stem cells. DNA research: an international journal for rapid publication of reports on genes and genomes. 2009; 16(1):45-58. doi: 10.1093/dnares/dsn030 PMID: 19001483; PubMed Central PMCID: PMC2644350.
34. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014; 157(6):1262-78. doi: 10.1016/j.cell.2014.05.010 PMID: 24906146.
35. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell research. 2008; 18(1):134-47. doi: 10.1038/cr.2007.111 PMID: 18157161.
36. Qin W, Sundaram M, Wang Y, Zhou H, Zhong S, Chang CC, et al. Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. J Biol Chem. 2011; 286(31):27769-80. doi: 10.1074/jbc.M110.203679 PMID: 21676879; PubMed Central PMCID: PMC3149367.
37. Huff MW, Hegele RA. Apolipoprotein C-III: going back to the future for a lipid drug target. Circulation research. 2013; 112(11):1405-8. doi: 10.1161/CIRCRESAHA.113.301464 PMID: 23704213.
38. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008; 322 (5908):1702-5. doi: 10.1126/science.1161524 PMID: 19074352; PubMed Central PMCID: PMC2673993.
39. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease. N Engl J Med. 2014. doi: 10.1056/NEJMoa1308027 PMID: 24941082.
40. The TG, Hdl Working Group of the Exome Sequencing Project NHL, Blood I. Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease. N Engl J Med. 2014. doi: 10.1056/NEJMoa1307095 PMID: 24941081.
41. Tsai J, Qiu W, Kohen-Avramoglu R, Adeli K. MEK-ERK inhibition corrects the defect in VLDL assembly in HepG2 cells: potential role of ERK in VLDL-ApoB100 particle assembly. Arterioscler Thromb Vasc Biol. 2007; 27(1):211-8. doi: 10.1161/01.ATV.0000249861.80471.96 PMID: 17038630.
42. Jammart B, Michelet M, Pecheur EI, Parent R, Bartosch B, Zoulim F, et al. Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells. Journal of virology. 2013; 87(9):5065-80. doi: 10.1128/JVI.01405-12 PMID: 23427158; PubMed Central PMCID: PMC3624324.
43. Mulvihill EE, Assini JM, Lee JK, Allister EM, Sutherland BG, Koppes JB, et al. Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance. Diabetes. 2011; 60(5):1446-57. doi: 10.2337/db10-0589 PMID: 21471511; PubMed Central PMCID: PMC3292317.
44. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature medicine. 2004; 10(12):1344-51. Epub 2004/11/09. doi: 10.1038/nm1135 PMID: 15531889.
45. Zhang F, Ahlborn TE, Li C, Kraemer FB, Liu J. Identification of Egr1 as the oncostatin M-induced transcription activator that binds to sterol-independent regulatory element of human LDL receptor promoter. J Lipid Res. 2002; 43(9):1477-85. PMID: 12235180.
46. Li C, Kraemer FB, Ahlborn TE, Liu J. Induction of low density lipoprotein receptor (LDLR) transcription by oncostatin M is mediated by the extracellular signal-regulated kinase signaling pathway and the repeat 3 element of the LDLR promoter. J Biol Chem. 1999; 274(10):6747-53. PMID: 10037774.
47. Kong W, Abidi P, Kraemer FB, Jiang JD, Liu J. In vivo activities of cytokine oncostatin M in the regulation of plasma lipid levels. J Lipid Res. 2005; 46(6):1163-71. Epub 2005/03/18. doi: M400425-JLR200 [pii] doi: 10.1194/jlr.M400425-JLR200 PMID: 15772430.
48. Pak YK, Kanuck MP, Berrios D, Briggs MR, Cooper AD, Ellsworth JL. Activation of LDL receptor gene expression in HepG2 cells by hepatocyte growth factor. J Lipid Res. 1996; 37(5):985-98. PMID: 8725151.
49. Do HT, Tselykh TV, Makela J, Ho TH, Olkkonen VM, Bornhauser BC, et al. Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap). J Biol Chem. 2012; 287(16):12602-11. doi: 10.1074/jbc.M112.341248 PMID: 22378787; PubMed Central PMCID: PMC3339997.
50. Kotzka J, Knebel B, Avci H, Jacob S, Nitzgen U, Jockenhovel F, et al. Phosphorylation of sterol regulatory element-binding protein (SREBP)-1a links growth hormone action to lipid metabolism in hepatocytes. Atherosclerosis. 2010; 213(1):156-65. doi: 10.1016/j.atherosclerosis2010.08.046. PMID: 20863500.
51. Vargas NB, Brewer BY, Rogers TB, Wilson GM. Protein kinase C activation stabilizes LDL receptor mRNA via the JNK pathway in HepG2 cells. J Lipid Res. 2009; 50(3):386-97. doi: 10.1194/jlr.M800316-JLR200 PMID: 18936517; PubMed Central PMCID: PMC2638102.
52. Yashiro T, Nanmoku M, Shimizu M, Inoue J, Sato R. 5-Aminoimidazole-4-carboxamide ribonucleoside stabilizes low density lipoprotein receptor mRNA in hepatocytes via ERK-dependent HuR binding to an AU-rich element. Atherosclerosis. 2013; 226(1):95-101. doi: 10.1016/j.atherosclerosis.2012.09.033 PMID: 23116706.
53. Kiss-Toth E, Bagstaff SM, Sung HY, Jozsa V, Dempsey C, Caunt JC, et al. Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. J Biol Chem. 2004; 279(41):42703-8. doi: 10.1074/jbc.M407732200 PMID: 15299019.
54. Jin G, Yamazaki Y, Takuwa M, Takahara T, Kaneko K, Kuwata T, et al. Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood. 2007; 109(9):3998-4005. doi: 10.1182/blood-2006-08-041202 PMID: 17227832.
55. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008; 57(5):1414-8. doi: 10.2337/db07-1552 PMID: 18285556.
56. Buhl ES, Jessen N, Pold R, Ledet T, Flyvbjerg A, Pedersen SB, et al. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes. 2002; 51(7):2199-206. PMID: 12086950.
57. Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis. 2008; 201(2):266-73. doi: 10.1016/j.atherosclerosis.2008.02.004 PMID: 18355829.